The discovery of JAK2617F mutation paved the way for the development of small molecule
inhibitors of JAK1/2 resulting in first approved JAK1/2 inhibitor, ruxolitinib, for the treatment of …

The introduction of JAK inhibitors, leading to regulatory approval of ruxolitinib, represents a
major therapeutic advance in myelofibrosis (MF). Most patients experience reduction in …

Hematopoietic cell transplantation (HCT) is the only curative therapeutic modality for
myelofibrosis (MF) at present. The optimal timing of HCT is not known in the presence of …

Allogeneic hematopoietic stem-cell transplantation (HSCT) is, at present, the only potentially
curative therapy for myelofibrosis (MF). Despite many improvements, outcomes of HSCT are …

Myelofibrosis (MF) is a heterogeneous disease for which long‐term, effective medical
therapeutic options are currently limited. The role of allogeneic haematopoietic stem cell …

Myelofibrosis (MF) is a BCR-ABL1–negative myeloproliferative neoplasm characterized by
clonal myeloproliferation, dysregulated kinase signaling, and release of abnormal cytokines …

The JAK1/JAK2 inhibitor ruxolitinib produced significant reductions in splenomegaly and
symptomatic burden and improved survival in patients with myelofibrosis (MF), irrespective …

The impact of Janus kinase (JAK) 1/2 inhibitor therapy before allogeneic hematopoietic cell
transplantation (HCT) has not been studied in a large cohort in myelofibrosis (MF). In this …

Introduction: Myelofibrosis (MF) is characterized by bone marrow fibrosis, abnormalities in
peripheral counts, extramedullary hematopoiesis, splenomegaly and an increased risk of …

Myelofibrosis (MF) is a BCR-ABL1–negative myeloproliferative neoplasm that is mainly
characterised by reactive bone marrow fibrosis, extramedullary haematopoiesis, anaemia …